|
Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia Clinical research trials and Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia. Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia clinical trial. Subjects frequently obtain the most expert healthcare possible for their Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia  Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia
Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia
For Condition: Pulmonary Hypertension,Sickle Cell Anemia
Status: Recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: The purpose of this study is to determine how often people with sickle cell anemia develop pulmonary hypertension-a serious disease in which blood pressure in the artery to the lungs is elevated. Men and women 18 years of age and older with sickle cell anemia may be eligible for this study. Participants will undergo an evaluation at Howard University's Comprehensive Sickle Cell Center in Washington, D.C. or at the National Institutes of Health in Bethesda, Maryland. It will include the following: -medical history -physical examination -blood collection (no more than 50 ml., or about 1/3 cup) to confirm the diagnosis of sickle cell anemia, sickle cell trait or beta-thalassemia (Some blood will be stored for future research testing on sickle cell anemia.) -echocardiogram (ultrasound test of the heart) to check the pumping action of the heart and the rate at which blood travels through the tricuspid valve. Following this evaluation, a study nurse will contact participants twice a month for 2 months and then once every 3 months for the next 3 years for a telephone interview. The interview will include questions about general health and recent health-related events, such as hospitalizations or emergency room visits.
Details: Sickle cell anemia is an autosomal recessive disorder and the most common genetic disease affecting African-Americans. Approximately 0.15% of African-Americans are homozygous for sickle cell disease, and 8% have sickle cell trait. Acute pain crisis, acute chest syndrome (ACS), and secondary pulmonary hypertension are common complications of sickle cell anemia. Mortality rates of sickle cell patients with pulmonary hypertension are significantly increased as compared to patients without pulmonary hypertension. Recent studies report up to 40% mortality at 22 months after detection of elevated pulmonary artery pressures in sickle cell patients. Furthermore, pulmonary hypertension is thought to occur in up to 30% of clinic patients with sickle cell anemia. This study is designed to determine the prevalence and prognosis of secondary pulmonary hypertension in adult patients with sickle cell anemia, and to determine whether genetic polymorphisms in candidate genes contribute to its development.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: All volunteer subjects must be at least 18 years of age and must be able to provide informed, written consent for participation in this study. Decisional impaired subjects will be included in this study provided that a legally authorized representative provides fully informed consent. Sickle Cell Patients: Male and females over 18 years of age. Diagnosis of sickle cell disease (electrophoretic documentation of SS, SC, or S-beta thallassemia genotype is required). Control Subjects: Male and female African American subjects over 18 years of age. Exclusion of sickle cell disease (electrophoretic documentation of hemoglobin A is required) EXCLUSION CRITERIA: Sickle Cell Patients: Hb A-only phenotype and sickle cell trait. Decisionally impaired subjects without a legally authorized representative who are unable to have a next-of-kin surrogate appointed through the services of an ethics consult. Control Subjects: Diagnosis of sickle cell disease (electrophoretic documentation of SS, SC, or S-beta thallassemia genotype is required). Decisionally impaired subjects without a legally authorized representative who are unable to have a next-of-kin surrogate appointed through the services of an ethics consult.
Total Enrollment: 370
Location and Contact Information:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 010088; 01-DK-0088
Study Start Date: February 8, 2001
Record last reviewed: January 2, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00011648
Other Sickle Cell Anemia Studies:
1. Inhaled Nitric Oxide and Transfusion Therapy for Patients with Sickle Cell Anemia and Secondary Pulmonary Hypertension
2. Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents with Infants at Risk of Sudden Death
3. Phase III Randomized Study of UT-15 in Patients with Primary Pulmonary Hypertension
4. Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
5. A Transition Study From Flolan® to Remodulin® in Patients with Pulmonary Arterial Hypertension
Related Studies:
Other Sickle Cell Anemia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Secondary Pulmonary Hypertension in Adults with Sickle Cell Anemia
|
|
|
|
|
|
|
|
